Search Results - "Bochtler, T."

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Krämer, A., Bochtler, T., Pauli, C., Baciarello, G., Delorme, S., Hemminki, K., Mileshkin, L., Moch, H., Oien, K., Olivier, T., Patrikidou, A., Wasan, H., Zarkavelis, G., Pentheroudakis, G., Fizazi, K.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing cancer of unknown primary (CUP).•The guideline covers CUP diagnosis, risk…”
Get full text

Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia by Bochtler, T, Fröhling, S, Krämer, A

“…Genetic abnormalities are a hallmark of cancer. Hereby, cytogenetic aberrations and small-scale abnormalities, such as single-nucleotide variations and…”
Get full text

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo by Chaturvedi, A, Herbst, L, Pusch, S, Klett, L, Goparaju, R, Stichel, D, Kaulfuss, S, Panknin, O, Zimmermann, K, Toschi, L, Neuhaus, R, Haegebarth, A, Rehwinkel, H, Hess-Stumpp, H, Bauser, M, Bochtler, T, Struys, E A, Sharma, A, Bakkali, A, Geffers, R, Araujo-Cruz, M M, Thol, F, Gabdoulline, R, Ganser, A, Ho, A D, von Deimling, A, Rippe, K, Heuser, M, Krämer, A

“…Neomorphic mutations in isocitrate dehydrogenase 1 ( IDH1 ) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead…”
Get full text

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing by Christopoulos, P., Kirchner, M., Roeper, J., Saalfeld, F., Janning, M., Bozorgmehr, F., Magios, N., Kazdal, D., Volckmar, A.L., Brückner, L.M., Bochtler, T., Kriegsmann, M., Endris, V., Penzel, R., Kriegsmann, K., Eichhorn, M., Herth, F.J.F., Heussel, C.P., El Shafie, R.A., Schneider, M.A., Muley, T., Meister, M., Faehling, M., Fischer, J.R., Heukamp, L., Schirmacher, P., Bischoff, H., Wermke, M., Loges, S., Griesinger, F., Stenzinger, A., Thomas, M.

“…•EGFR variant, TP53 and brain status together predict survival in EGFR+ NSCLC (ENS).•Co-mutations beyond TP53 are rare and their clinical significance remains…”
Get full text

Karyotype complexity and prognosis in acute myeloid leukemia by Stölzel, F, Mohr, B, Kramer, M, Oelschlägel, U, Bochtler, T, Berdel, W E, Kaufmann, M, Baldus, C D, Schäfer-Eckart, K, Stuhlmann, R, Einsele, H, Krause, S W, Serve, H, Hänel, M, Herbst, R, Neubauer, A, Sohlbach, K, Mayer, J, Middeke, J M, Platzbecker, U, Schaich, M, Krämer, A, Röllig, C, Schetelig, J, Bornhäuser, M, Ehninger, G

“…A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid…”
Get full text

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia by Kayser, S, Benner, A, Thiede, C, Martens, U, Huber, J, Stadtherr, P, Janssen, J W G, Röllig, C, Uppenkamp, M J, Bochtler, T, Hegenbart, U, Ehninger, G, Ho, A D, Dreger, P, Krämer, A

“…The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain…”
Get full text

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia by Balss, J, Thiede, C, Bochtler, T, Okun, J G, Saadati, M, Benner, A, Pusch, S, Ehninger, G, Schaich, M, Ho, A D, von Deimling, A, Krämer, A, Heilig, C E

“…Mutations in isocitrate dehydrogenases (IDHs) 1 and 2 frequently occur in acute myeloid leukemia (AML) and result in the production of the oncometabolite d…”
Get full text

Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled on to the CUPISCO study by Westphalen, C.B., Federer-Gsponer, J., Pauli, C., Karapetyan, A.R., Chalabi, N., Durán-Pacheco, G., Beringer, A., Bochtler, T., Cook, N., Höglander, E., Jin, D.X., Losa, F., Mileshkin, L., Moch, H., Ross, J.S., Sokol, E.S., Tothill, R.W., Krämer, A.

“…Patients with unfavorable carcinoma of unknown primary origin (CUP) have an extremely poor prognosis of ∼1 year or less, stressing the need for more tailored…”
Get full text

Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay by Menon, R, Mueller, J, Lakis, S, Hube, A, Bochtler, T, Wesseler, C, Griesinger, F, Loeffler, H, Langenbuch, T, Brandts, C, Garcia, A.P, Krämer, A, Heuckmann, J, Heukamp, L

“…An abstract of a study by Menon et al analyzing identification of therapeutically targetable genomic alterations in a cohort of patients with carcinomas of…”
Get full text

Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders by Bochtler, T, Kirsch, M, Maier, B, Bachmann, J, Klingmüller, U, Anderhub, S, Ho, A D, Krämer, A

“…Constitutive tyrosine kinase activation by reciprocal chromosomal translocation is a common pathogenetic mechanism in chronic myeloproliferative disorders…”
Get full text

Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom) by Boeckel, G. R., Pouyiourou, M., Claßen, L., Bochtler, T., Krämer, A.

“…Zusammenfassung Bei Krebserkrankungen mit unbekanntem Primärtumor (CUP, „carcinoma of unknown primary site“) handelt es sich um ein heterogenes onkologisches…”
Get full text

Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases by Bochtler, T., Hensel, M., Lorenz, H.-M., Ho, A. D., Mahlknecht, U.

Get full text

174P Frequency and prognostic value of circulating tumor cells in cancer of unknown primary by Pouyiourou, M., Riethdorf, S., Bochtler, T., Coith, C., Kraft, B., Hielscher, T., Stenzinger, A., Pantel, K., Krämer, A.

Get full text

519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study by Mileshkin, L., Bochtler, T., Beringer, A., Mueller-Ohldach, M., Surinach, A., Perret, C., Thomas, M., Gondos, A., Krämer, A.

Get full text

738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial by Pouyiourou, M., Kraft, B., Wohlfromm, T., Stahl, M., Kubuschok, B., Löffler, H., Hacker, U.T., Huebner, G., Westphalen, C.B., Bitzer, M., Ernst, T., Schuett, P., Hielscher, T., Delorme, S., Stenzinger, A., Bochtler, T., Krämer, A.

Get full text

LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP) by Mileshkin, L., Bochtler, T., Pauli, C., Durán-Pacheco, G., Arslan, C., Bigot, F., Chalabi, N., Cook, N., Italiano, A., Losa, F., Menezes, J., Michaud, C., Ozguroglu, M., Pazo Cid, R.A., Ross, J.S., Shiu, K-K., Stahl, M., Thomas, M., Moch, H., Krämer, A.

Get full text

1804P Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO by Westphalen, C.B., Karapetyan, A., Beringer, A., Bochtler, T., Chalabi, N., Cook, N., Duran-Pacheco, G., Golding, S., Höglander, E., Losa, F., Mileshkin, L., Moch, H., Pauli, C., Ross, J., Sokol, E., Tothill, R., Krämer, A.

Get full text

A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience by Pauli, C., Bochtler, T., Mileshkin, L., Baciarello, G., Losa, F., Ross, J., Pentheroudakis, G., Zarkavelis, G., Yalcin, S., Özgüroğlu, M., Beringer, A., Foser, S., Scarato, J., Mueller-Ohldach, M., Moch, H., Krämer, A.

Get full text

2037PA challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience by Pauli, C, Bochtler, T, Mileshkin, L, Baciarello, G, Losa, F, Ross, J, Pentheroudakis, G, Zarkavelis, G, Yalcin, S, Özgüroğlu, M, Beringer, A, Foser, S, Scarato, J, Mueller-Ohldach, M, Moch, H, Krämer, A

“…Abstract Background The CUPISCO trial (NCT03498521) is an ongoing, phase II, randomised, multicentre study comparing molecularly-guided therapy with standard…”
Get full text

2037P - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience by Pauli, C., Bochtler, T., Mileshkin, L., Baciarello, G., Losa, F., Ross, J., Pentheroudakis, G., Zarkavelis, G., Yalcin, S., Özgüroğlu, M., Beringer, A., Foser, S., Scarato, J., Mueller-Ohldach, M., Moch, H., Krämer, A.

“…The CUPISCO trial (NCT03498521) is an ongoing, phase II, randomised, multicentre study comparing molecularly-guided therapy with standard platinum-based…”
Get full text